Pelvic Congestion Syndrome Treatment Market
Pelvic Congestion Syndrome Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028
Analysis of Pelvic Congestion Syndrome Treatment Market Covering 30 + Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pelvic Congestion Syndrome Treatment: Market Insights
Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities.
According to a study reported in 2016, it is estimated that 10 million women suffer from pelvic congestion syndrome with approximately 7 million women avoid seeking treatment. Worldwide prevalence of chronic pelvic pain is estimated to vary from 26.6% in Egypt and 5.7% in Austria. The economic scenario of the pelvic congestion syndrome has a great impact.
The annual medical cost of pelvic congestion syndrome diagnosis and pelvic congestion syndrome treatment is estimated to be around US$ 1.2 billion and the cost of lost productivity in patients with pelvic congestion syndrome treatment is estimated to be around US$ 15 billion annually.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Pelvic Congestion Syndrome Treatment: Market Dynamics
Pelvic congestion syndrome is a common issue among women between the 20 and 50 years of age. Mostly doctors prescribed painkillers for pelvic congestion syndrome treatment to reduce the pain. Apart from this hormonal therapy is also given to reduce the congestion in pelvic congestion syndrome treatment. Various treatment procedures in pelvic congestion syndrome treatment expected to drive the market. Hormonal treatment helps to reduce congestion and blood flow of the viscous vein.
If this pelvic congestion syndrome treatment fails, minimally invasive therapies such as nonsurgical embolization are mostly used in pelvic congestion syndrome treatment. Advancement in latest technologies and procedures is likely to anticipate to boost the pelvic congestion syndrome treatment market. Lack of skilled professional and lack of awareness among people may restrain the growth of pelvic congestion syndrome treatment market. Cost of embolization procedures is also another factor that may hinder the pelvic congestion syndrome treatment market.
Pelvic Congestion Syndrome Treatment Market: Overview
Pelvic congestion syndrome treatment market is expected to have gradual growth. Medical pelvic congestion syndrome treatment includes danazol, psychotherapy, progestin, phlebotonics, gonadotropins receptor agonists (GnRH) which is done by hormone replacement therapy, nonsteroidal anti-inflammatory drugs, and dihydroergotamine. Also some of the latest technologies which consists of transcatheter embolotherapy are being currently used in pelvic congestion syndrome treatment. Medical therapy has shown to provide relief to the patients but the outcome is for a shorter period.
However, Gonadotrophin releasing hormone agonist called goserelin has shown satisfactory results in pelvic congestion syndrome treatment pain. Apart from this, hysterectomy with oophorectomy has proven to provide moderate relief to patients with pelvic congestion syndrome treatment. Embolotherapy has been an exciting therapy in pelvic congestion syndrome treatment. With advances in medical sciences, pelvic congestion syndrome treatment market is expected to have significant growth in next few years.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Pelvic Congestion Syndrome Treatment Market: Region-wise Outlook
On the basis of geography, the global pelvic congestion syndrome treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. North America is expected to dominate the global pelvic congestion syndrome treatment market due to advancement in technology, high healthcare facilities and improve infrastructure which will facilitate the growth of pelvic congestion syndrome treatment market.
Europe is also likely anticipate to boost the overall growth of pelvic congestion syndrome treatment market owing to adoption of new treatment options and availability of drugs and increase in procedures of injectable used for the pelvic congestion syndrome treatment.
Asia Pacific is expected to have the potential to drive the global pelvic congestion syndrome treatment market due to increase in prevalence of pelvic congestion syndrome. According to one report, the prevalence rate of chronic pelvic pain in developing countries accounts to 5.2% in India and 43.2% in Thailand. Among these cases, pelvic congestion syndrome reports 16% to 31% of all cases which is likely to have a considerable growth in pelvic congestion syndrome treatment market.
Middle East and Africa has less potential to drive the pelvic congestion syndrome treatment market due to lack of awareness among people and poor healthcare facilities may restrain the growth of the pelvic congestion syndrome treatment market.
Pelvic Congestion Syndrome Treatment Market: Key Players
Some of the key players present across the value chain of the global pelvic congestion syndrome treatment market are Sanofi, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius Kabi USA,LLC
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
The regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- The Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
Pelvic Congestion Syndrome Treatment Market: Segmentation
The global pelvic congestion syndrome treatment market is segmented by disease type, medication and distributional channel.
- Segmentation by Disease Type
- Primary Pelvic Congestion Syndrome Treatment
- Secondary Pelvic Congestion Syndrome Treatment
- Segmentation by Medication
- NSAIDs (nonsteroidal anti-inflammatory drugs) Pelvic Congestion Syndrome Treatment
- Psychotherapy Pelvic Congestion Syndrome Treatment
- Analgesics Pelvic Congestion Syndrome Treatment
- Dihydroergotamine
- Progestins
- Others
- Segmentation by Distributional Channel
- Hospital
- Diagnostics laboratories
- Gynecology Clinics
- Ambulatory Surgical Centers
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Disease Type 6.2. Medication 6.3. Distributional Channel 7. Global Market Analysis and Forecast, By Disease Type 7.1. Primary Pelvic Congestion Syndrome Treatment 7.2. Secondary Pelvic Congestion Syndrome Treatment 8. Global Market Analysis and Forecast, By Medication 8.1. NSAIDs (nonsteroidal anti-inflammatory drugs) 8.2. Psychotherapy 8.3. Analgesics 8.4. Dihydroergotamine 8.5. Progestins 8.6. Others 9. Global Market Analysis and Forecast, By Distributional Channel 9.1. Hospital 9.2. Diagnostics laboratories 9.3. Gynecology Clinics 9.4. Ambulatory Surgical Centers 10. Global Market Analysis and Forecast, By Region 10.1. North America 10.2. Latin America 10.3. Western Europe 10.4. Eastern Europe 10.5. Asia Pacific 10.6. East Asia 10.7. MEA 11. North America Sales Analysis and Forecast, by Key Segments and Countries 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 15. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 16. East Asia Sales Analysis and Forecast, by Key Segments and Countries 17. MEA Sales Analysis and Forecast, by Key Segments and Countries 18. Sales Forecast by Disease Type, Medication, and Distributional Channel for 30 Countries 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 20. Company Profile 20.1. Sanofi 20.2. TOLMAR Inc. 20.3. Actiza Pharmaceuticals 20.4. Pfizer 20.5. Debio RP 20.6. AbbVie Inc. 20.7. AstraZeneca 20.8. Novartis Pharmaceuticals Corporation 20.9. Indivior Inc. 20.10. Pernix Ireland Pain Limited 20.11. ALZA Corporation 20.12. Fresenius Kabi USA, LLC
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Disease Type
Table 3: Global Market US$ Mn Forecast by Medication
Table 4: Global Market US$ Mn Forecast by Distributional Channel
Table 5: North America Market US$ Mn Forecast by Country
Table 6: North America Market US$ Mn Forecast by Disease Type
Table 7: North America Market US$ Mn Forecast by Medication
Table 8: North America Market US$ Mn Forecast by Distributional Channel
Table 9: Latin America Market US$ Mn Forecast by Country
Table 10: Latin America Market US$ Mn Forecast by Disease Type
Table 11: Latin America Market US$ Mn Forecast by Medication
Table 12: Latin America Market US$ Mn Forecast by Distributional Channel
Table 13: Western Europe Market US$ Mn Forecast by Country
Table 14: Western Europe Market US$ Mn Forecast by Disease Type
Table 15: Western Europe Market US$ Mn Forecast by Medication
Table 16: Western Europe Market US$ Mn Forecast by Distributional Channel
Table 17: Eastern Europe Market US$ Mn Forecast by Country
Table 18: Eastern Europe Market US$ Mn Forecast by Disease Type
Table 19: Eastern Europe Market US$ Mn Forecast by Medication
Table 20: Eastern Europe Market US$ Mn Forecast by Distributional Channel
Table 21: Asia Pacific Market US$ Mn Forecast by Country
Table 22: Asia Pacific Market US$ Mn Forecast by Disease Type
Table 23: Asia Pacific Market US$ Mn Forecast by Medication
Table 24: Asia Pacific Market US$ Mn Forecast by Distributional Channel
Table 25: East Asia Market US$ Mn Forecast by Country
Table 26: East Asia Market US$ Mn Forecast by Disease Type
Table 27: East Asia Market US$ Mn Forecast by Medication
Table 28: East Asia Market US$ Mn Forecast by Distributional Channel
Table 29: MEA Market US$ Mn Forecast by Country
Table 30: MEA Market US$ Mn Forecast by Disease Type
Table 31: MEA Market US$ Mn Forecast by Medication
Table 32: MEA Market US$ Mn Forecast by Distributional Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 10: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 14: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 15: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 17: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 18: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 19: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 20: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 22: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 23: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 24: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 26: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 27: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 28: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 29: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 30: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 31: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 32: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Pelvic Congestion Syndrome Treatment Market